-
Product Insights
Influenza A Virus, H1N1 Subtype Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Influenza A Virus, H1N1 Subtype Infections - Drugs In Development, 2023’, provides an overview of the Influenza A Virus, H1N1 Subtype Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Klebsiella Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Klebsiella Infections - Drugs In Development, 2023’, provides an overview of the Klebsiella Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Klebsiella Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Seasonal Influenza – Drugs In Development, 2023
Global Markets Direct’s, ‘Seasonal Influenza - Drugs In Development, 2023’, provides an overview of the Seasonal Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development for Seasonal Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Escherichia coli Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Escherichia coli Infections - Drugs In Development, 2023’, provides an overview of the Escherichia coli Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Escherichia coli Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Klebsiella pneumoniae Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Klebsiella pneumoniae Infections - Drugs In Development, 2023’, provides an overview of the Klebsiella pneumoniae Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Influenza A Virus, H3N2 Subtype Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Influenza A Virus, H3N2 Subtype Infections - Drugs In Development, 2023’, provides an overview of the Influenza A Virus, H3N2 Subtype Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Hospital Acquired Pneumonia (HAP) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hospital Acquired Pneumonia (HAP) - Drugs In Development, 2023’, provides an overview of the Hospital Acquired Pneumonia (HAP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Ventilator Associated Pneumonia (VAP) – Drugs In Development, 2023
Global Markets Direct’s, ‘Ventilator Associated Pneumonia (VAP) - Drugs In Development, 2023’, provides an overview of the Ventilator Associated Pneumonia (VAP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Osteomyelitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Osteomyelitis - Drugs In Development, 2023’, provides an overview of the Osteomyelitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Osteomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Cystic Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Cystic Fibrosis - Drugs In Development, 2023’, provides an overview of the Cystic Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...